Assertio reports Q4 adjusted EBITDA loss of $4.1M; Rolvedon sales drop to $0.4M from $15.4M

Assertio Holdings, Inc.

Rolvedon Q4 net sales $0.4M vs $15.4M YoY; sell-in in Q3 2025 covered two quarters of demand, sales under new label expected Q2 2026.
Sympazan net sales grew to $3.1M from $2.5M; Indocin flat at $5.5M.
Gross margin improved to 75% from 61% on product mix and inventory write-downs in prior year.
Adjusted EBITDA loss $4.1M vs income $3.4M last year; cash dropped to $63.4M from $93.4M in Q3.
FY2026 guidance: net product sales $110M-$125M, Adj EBITDA $28M-$40M; CEO prioritizes Rolvedon and disciplined oncology build.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Assertio Holdings, Inc. reported financial results for the fourth quarter ended December 31, 2025.

Period: the fourth quarter ended December 31, 2025
Result: reported results

Exact text from the filing

today reported financial results for the fourth quarter and full year ended December 31, 2025.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Assertio Holdings, Inc. updated its the fiscal year ended December 31, 2025 guidance (initiated).

Period: the fiscal year ended December 31, 2025
Guidance: initiated
Result: reported results

Exact text from the filing

Assertio Reports Fourth Quarter and Full Year 2025 Financial Results Delivers FY2025 Net Product Sales and Adjusted EBITDA Above Guidance Expects Net Product Sales between $110M-$125M and Adjusted EBITDA between $28M-$40M in FY2026

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Assertio Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001808665-26-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.